Compare Moderna, Inc. (MRNA) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Nuwellis Inc — how do they compare? Moderna, Inc. trades at $196.81 (market cap $78.65B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Moderna, Inc. is far larger — about 35750× Nuwellis Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Nuwellis Inc for 26 Days on average.
| MRNA | NUWE | |
|---|---|---|
Market Cap | $78.65B | $2.20M |
Volume | 37,373,437 | 121,544 |
Sector | Health | Health |
52-Week High | $203.46 | $146.65 |
52-Week Low | $22.36 | $0.68 |
Typical Hold Time | 59 Days | 26 Days |
Enterprise Value | $74.80B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
